CJC-1295 / Ipamorelin – 5/5mg

Researchers who buy this CJC-1295 / Ipamorelin research peptide blend are typically studying combined-receptor growth-hormone-axis signaling — pairing a GHRH-receptor agonist with a selective ghrelin-receptor (GHS-R1a) agonist in a single fixed-ratio preparation. Each compound acts through a distinct receptor pathway; the summary below reflects the published preclinical and clinical literature on each component and is provided strictly for research and educational reference — it does not describe an intended effect of this product in humans or animals.

In this reference:

• What Is This Blend?
• CJC-1295: Mechanism and Research
• Ipamorelin: Mechanism and Research
• Why Researchers Study This Combination
• Chemical Identity
• Purity, Storage & Quality
• Frequently Asked Questions

What Is This Blend?

This vial supplies a fixed-ratio, 5mg/5mg lyophilized combination of two distinct growth-hormone-axis research peptides: CJC-1295 (without DAC), a synthetic growth hormone-releasing hormone (GHRH) analog, and Ipamorelin, a selective ghrelin-receptor (GHS-R1a) agonist. Each compound is independently well-characterized in the published pharmacology literature, and their co-administration is a common research design for studying combined-receptor GH-axis stimulation rather than either receptor pathway in isolation.

CJC-1295: Mechanism and Research

CJC-1295 is a synthetic analog of the first 29 residues of native GHRH — the minimal sequence reported to retain full GHRH-receptor activity — modified to resist the rapid enzymatic degradation that limits unmodified GHRH(1-29) fragments such as Sermorelin. Published pharmacokinetic literature distinguishes CJC-1295 with DAC (drug affinity complex, which covalently binds circulating albumin to extend plasma half-life to several days) from CJC-1295 without DAC, the shorter-acting variant supplied in this blend.

A randomized, placebo-controlled, double-blind ascending-dose trial in healthy adults reported that a single injection of CJC-1295 produced dose-dependent increases in mean plasma growth-hormone concentrations of 2- to 10-fold sustained for 6 or more days, and mean plasma IGF-1 concentrations increased 1.5- to 3-fold for 9 to 11 days (Teichman SL, et al., J Clin Endocrinol Metab. 2006;91(3):799-805; PMID 16352683). Separate preclinical research in a GHRH-knockout mouse model reported that once-daily CJC-1295 administration normalized growth in animals lacking endogenous GHRH signaling, supporting its characterization as a functional GHRH-receptor agonist (PMID 16822960).

CJC-1295 is not an FDA-approved drug for any indication and has not completed the clinical-trial pathway required for approval. It is sold exclusively for in vitro and laboratory research use.

Ipamorelin: Mechanism and Research

Ipamorelin is a selective agonist at the ghrelin/growth hormone secretagogue receptor (GHS-R1a), first characterized as the most receptor-selective compound in its class — activating GH-axis signaling in tested animal models with markedly less elevation of ACTH, cortisol, and prolactin than earlier, broader-acting secretagogue peptides (Raun K, et al., Eur J Endocrinol. 1998;139(5):552-561; PMID 9849822). A full literature review of Ipamorelin’s mechanism, chemical identity, and the one controlled human trial in which it has been studied (a gastrointestinal-motility indication, PMID 25331030) is available on its own dedicated page: Ipamorelin – 10mg.

Why Researchers Study This Combination

Because CJC-1295 and Ipamorelin engage two separate receptors in the same GH-axis signaling pathway — GHRHR and GHS-R1a, respectively — published pharmacology has proposed that co-administration may produce a more complete or synergistic GH-axis stimulation profile than either compound alone, since the two mechanisms are not mutually redundant. Researchers studying combined-receptor GH-axis engagement, or comparing single-receptor versus dual-receptor stimulation protocols, are the typical audience for this fixed-ratio preparation. This combination-research design is distinct from, and should not be conflated with, the human clinical-trial evidence that exists independently for each individual compound (summarized on each compound’s own product page).

Chemical Identity

Purity, Storage & Quality

First Class Science supplies this CJC-1295 / Ipamorelin blend at research-grade purity, with each component independently verified by third-party HPLC testing and mass spectrometry prior to blending. A Certificate of Analysis is available for every batch at our Certificate of Analysis page.

Store the lyophilized (freeze-dried) compound at −20°C for long-term stability. This vial must be reconstituted with bacteriostatic or sterile water before laboratory use; after reconstitution, refrigerate at 2–8°C and use within 4–6 weeks. Avoid repeated freeze-thaw cycles and prolonged exposure to light or room-temperature conditions.

Important: This item is manufactured strictly for research purposes. It is not intended for human or veterinary use and is distributed solely for laboratory and scientific investigation.

Related Single-Compound Preparations

Laboratories designing protocols that isolate a single receptor pathway typically select the standalone Ipamorelin vial. A larger CJC-1295 / Ipamorelin – 10/10mg preparation of this same blend is also available, along with a related Tesamorelin / Ipamorelin Blend pairing Ipamorelin with a different, longer-studied GHRH analog.

Frequently Asked Questions

What is the purity of this blend?
Each component is independently verified via third-party HPLC and mass-spectrometry testing prior to blending, with a Certificate of Analysis published for each lot.

How should this CJC-1295 / Ipamorelin blend be stored?
Store the lyophilized powder at −20°C. After reconstitution, refrigerate at 2–8°C and use within 4–6 weeks; avoid repeated freeze-thaw cycles.

Is this blend approved for human or animal use?
No. Neither CJC-1295 nor Ipamorelin is an FDA-approved drug for any indication, and neither has completed the clinical-trial pathway required for approval. This product is sold exclusively for in vitro and laboratory research use.

Why are these two specific compounds combined?
CJC-1295 (a GHRH-receptor agonist) and Ipamorelin (a GHS-R1a agonist) engage two separate, non-redundant receptors in the GH-axis pathway. Researchers study the fixed-ratio combination to model dual-receptor stimulation, distinct from either compound’s single-receptor mechanism studied individually.

Has either compound been tested in humans?
Yes, independently. CJC-1295 was evaluated in a randomized, placebo-controlled ascending-dose trial in healthy adults (PMID 16352683). Ipamorelin was evaluated in a narrow, single-indication phase 2 trial for postoperative gastrointestinal motility (PMID 25331030, detailed on Ipamorelin’s own product page). Neither trial evaluated the fixed-ratio combination sold in this blend.

What does the Certificate of Analysis show?
The Certificate of Analysis published for each batch shows the HPLC purity result, mass-spectrometry molecular-weight confirmation, lot number, and test date for each component.

Shipping, Handling & Compliance

This blend ships as a lyophilized powder in a sealed glass vial, packaged to maintain cold-chain integrity in transit where applicable. All orders are subject to the research-use-only terms stated on this page, and First Class Science does not sell this or any other research peptide for human or veterinary administration under any circumstance.

Disclaimer: The research summarized above is drawn from third-party published studies conducted in animal, in vitro, or controlled clinical-trial contexts, examining each individual compound. It is provided for research and educational reference only and does not describe an intended use, effect, or benefit of this product for any person or animal. No published research has evaluated this specific fixed-ratio combination directly.

⊗ ALL ITEMS ARE SOLD FOR RESEARCH USE ONLY. This category covers strictly in vitro laboratory testing and scientific experimentation. Content on this site is for education only and does not authorize human or animal use of any kind, which is prohibited by law. Only trained, licensed professionals should handle these materials. Nothing sold here qualifies as a drug, food, or cosmetic, and none of it may be labeled, advertised, or used as such.